Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789851 | 0.86 | HCRTR1 (0.54) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL6962004 | 0.85 | MEN1 (0.48) | KMT2AMEN1HIF1ALMNAMAPT | |
| SCHEMBL20678058 | 0.85 | ALDH1A1 (0.45) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL29053673 | 0.80 | MEN1 (0.62) | KMT2AMEN1HIF1ALMNAMAPT | |
| SCHEMBL2566716 | 0.79 | LMNA (0.55) | KMT2AMEN1HIF1ALMNAMAPT | |
| SCHEMBL2492279 | 0.78 | LMNA (0.53) | KMT2AMEN1HIF1ALMNAMAPT | |
| Hydrochloric Acid SCHEMBL973645 | 0.78 | LMNA (0.54) | KMT2AMEN1HIF1ALMNAMAPT | |
| Hydrochloric Acid SCHEMBL28520522 | 0.78 | LMNA (0.54) | KMT2AMEN1HIF1ALMNAMAPT | |
| SCHEMBL6955280 | 0.78 | KMT2A (0.54) | KMT2AMEN1HIF1ALMNAMAPT | |
| SCHEMBL2775341 | 0.77 | LMNA (0.51) | KMT2AMEN1LMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115043757-B | Method for continuously preparing benzamidine hydrochloride | 南京桦冠生物技术有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-115043757-A | Method for continuously preparing benzamidine hydrochloride | 南京桦冠生物技术有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9403813-B2 | Azetidine amide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-0861071-A1 | BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997017949-A1 | BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | KMT2A 731/4885MEN1 476/4885HIF1A 285/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | KMT2A 1553/4885MEN1 829/4885HIF1A 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.